Does EDOXABAN Cause Malignant neoplasm progression? 16 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 16 reports of Malignant neoplasm progression have been filed in association with EDOXABAN (SAVAYSA). This represents 0.2% of all adverse event reports for EDOXABAN.
16
Reports of Malignant neoplasm progression with EDOXABAN
0.2%
of all EDOXABAN reports
9
Deaths
5
Hospitalizations
How Dangerous Is Malignant neoplasm progression From EDOXABAN?
Of the 16 reports, 9 (56.3%) resulted in death, 5 (31.3%) required hospitalization, and 2 (12.5%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for EDOXABAN. However, 16 reports have been filed with the FAERS database.
What Other Side Effects Does EDOXABAN Cause?
Anaemia (663)
Cerebral infarction (419)
Gastrointestinal haemorrhage (378)
Renal impairment (359)
Cerebrovascular accident (337)
Dyspnoea (331)
General physical health deterioration (315)
Haematuria (312)
Fall (298)
Cardiac failure (272)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which EDOXABAN Alternatives Have Lower Malignant neoplasm progression Risk?
EDOXABAN vs EDOXABAN TOSILATE
EDOXABAN vs EFALIZUMAB
EDOXABAN vs EFANESOCTOCOG ALFA
EDOXABAN vs EFAVIRENZ
EDOXABAN vs EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL